Hematology · 2 h ago
Methylphenidate reduced fatigue in a trial of patients with hematologic cancer
A double-blind, placebo-controlled crossover trial randomized 152 adults with hematologic cancer and fatigue to six weeks of methylphenidate or placebo, followed by crossover after a one-week washout. FACIT-F scores improved more during methylphenidate treatment, although adverse events were reported more often than with placebo.
- 152 adults were randomized in a placebo-controlled crossover trial.
- FACIT-F improvement favored methylphenidate by 5.0 points.
- Adverse events were more frequent during methylphenidate treatment.
Fatigue is a common unmet concern for people with hematologic cancer, but evidence for methylphenidate in this population has been limited. In this double-blind, placebo-controlled, two-period crossover trial, 152 adults with fatigue were assigned to six weeks of methylphenidate or placebo, had a treatment-free week, and then crossed over. Participants had a baseline fatigue score of at least 4 on a 0–10 scale; eligibility also excluded recent chemotherapy and concomitant psychopharmacologic treatment. The primary endpoint was change in Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) score.
FACIT-F scores improved by 8.9 points (95% CI, 7.3–10.4) after methylphenidate and 3.9 points (95% CI, 2.3–5.4) after placebo. The between-treatment difference was 5.0 points (95% CI, 2.8–7.2) in favor of methylphenidate. Other fatigue measures also favored methylphenidate. Adverse events were reported during 57% of methylphenidate periods versus 40% of placebo periods; the authors characterized toxicity as mild.
The findings support a potential pharmacologic option for fatigue in selected adults with hematologic cancer, but do not establish that the results apply to patients receiving recent chemotherapy or psychopharmacologic treatment, who were excluded. The abstract does not provide detailed adverse-event types or longer-term outcomes.
In practice
For adults with hematologic cancer and fatigue who resemble the trial population, methylphenidate improved fatigue scores more than placebo over six-week treatment periods. This provides evidence for a possible pharmacologic intervention, but does not establish routine use or longer-term benefit. Applicability is limited because patients who had chemotherapy within eight weeks or were taking psychopharmacologic treatment were excluded. Adverse events were more frequently reported with methylphenidate, although the abstract describes toxicity as mild and does not detail event types.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Journal of Clinical Oncology: Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical Trial ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.